Investors

Home  >  Investors  >  Press Releases  >  Press Release Details
View all news

Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team

06 March, 2019
Dr. Aurelia De Pauw to Oversee Clinical Operations

ORLEANS, Ontario, March 06, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery today announced the promotion of Aurelia De Pauw to Vice-President, Clinical Programs and Medical Affairs. In her new role Dr. De Pauw will be responsible for of all clinical operations and relations with the medical community, building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company. She will also drive the Company’s public education initiatives to build and increase awareness about the benefits, cautions, and adverse effects of cannabis-based treatment.

Aurelia De Pauw
Aurelia De Pauw, Vice President, Clinical Programs and Medical Affairs


Aurelia De Pauw holds a master’s degree and Ph.D. in Science from the Gembloux Agro-Bio Tech, University of Liege and the University of Namur, Belgium, followed by a five-year post-doctoral position in the field of stem cell therapy.  After establishing her career in basic sciences and regenerative therapy, she progressed from the laboratory bench to the bedside where she gained an even deeper appreciation of the impact of research on patients and caregivers. Aurelia has extensive experience in numerous therapeutic categories including oncology, drug abuse, endocrinology, dermatology and cardiology.  

“Aurelia had an immediate and significant impact since she joined Tetra last year and we are excited to entrust her with greater responsibility as we build on our medical affairs and clinical programs,” said Tetra Bio-Pharma CEO and CSO, Dr. Guy Chamberland. “What is most impressive about Dr. De Pauw is her drive to be part of the transformational process that happens when a drug is discovered, approved and then impacts the patients’ life. This is exactly what Tetra is all about.”

“I am proud of the confidence shown in me by Tetra Bio-Pharma’s leadership team and appreciate their support since I joined the Company as Director of Clinical Programs,” said Aurelia De Pauw.  “I believe that cannabinoid derived-drugs have the potential to offer patients new therapeutic alternatives that will provide meaningful improvement in their quality of life. That said, our role as a pharmaceutical company is to exercise the mandatory vigilance and best practices required in our clinical programs, right through commercialization.”

About Tetra Bio-Pharma 
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements 
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard                                     
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com       

Media Contact 
energi PR
Carol Levine
Carol.Levine@energipr.com
514-288-8500 ext. 226
Marissa Zanti
marissa.zanti@energipr.com 
416-425-9143 ext. 204

 

TETRA_150.jpg

Source: Tetra Bio-Pharma Inc

Categories: Press Releases
View all news